GHGillian Hall

Gillian Hall

*This is an algorithmically generated author record based on publicly available information.

Gillian Hall has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Kawasaki disease incidence in children and adolescents: an observational study in primary care

    by Gillian C Hall, Louise E Tulloh, Robert M R Tulloh

    Background Kawasaki disease is reported to be increasing in incidence and is the commonest childhood cause of acquired heart disease in the Western world. Aim To determine the current UK incidence of Kawasaki disease across childhood and adolescence; and investigate trends over time and season. Design and setting An observational, descriptive study in the UK. Method The Health Improvement Network (THIN) database of primary healthcare records was searched for codes or text indicating Kawasaki disease. Identified records were compared with a study case definition and a date of onset was assigned to cases. The incidence, age/sex distribution, and trend in seasonal and temporal distribution were estimated (2008–2012). Results A total of 110 episodes of Kawasaki disease in 109 children were identified from 3.9 million person-years observation. The incidence of Kawasaki disease was 2.8 per 100 000 person-years (95% confidence interval [CI] = 2.3 to 3.4) when aged P = 0.10 adjusted for sex and month), or between seasons (P = 0.65 adjusted for year and sex). Conclusion Although the incidence of Kawasaki disease remains low and has stabilised in the UK, GPs should recognise that the condition occurs throughout childhood and across the seasons.


  • Changes and predictors for change to thiazolidinedione prescribing in UK primary care following the rosiglitazone safety warning

    by G. C. Hall, H. T. Smith, B. Curtis, A. D. McMahon

    International audienceObjective To investigate switching from thiazolidinediones, and predictors for switching treatment, after publication of a meta-analysis reporting an increased risk of myocardial infarction associated with rosiglitazone use. Research design and methods Using THIN UK primary care database, the number of people with Type 2 diabetes prescribed either thiazolidinedione; rosiglitazone (n=10,062) or pioglitazone (n=4,454) and the rate of switching from thiazolidinediones (n=3,301 and 1,106 respectively), were computed for each month, May 2006 to January 2008. The probability of switching post-publication, May 2007 to January 2008, was modelled by logistic regression in a forward stepwise model. Variables included demographics, history of ischaemic heart disease (IHD), heart failure (HF) or stroke, risk factors for IHD, glucose-lowering and cardiovascular drug use, HbA1c and diabetes duration. Results There was a sharp increase in switching from both thiazolidinediones in summer 2007; rosiglitazone prescription numbers then decreased while pioglitazone prescribing increased. Switching from rosiglitazone was associated with IHD (adjusted odds ratio OR 1.72; 95% confidence intervals CI 1.47-2.00), insulin treatment (OR 5.10; 95% CI 3.21-8.10), HF (OR 2.26; 95% CI 1.62-3.18), recent sulphonylurea prescription (OR 1.33; 95% CI 1.17-1.51) sex (OR males v females 0.79; 95% CI 0.70, 0.90) and duration of therapy. Switching from pioglitazone was associated with HF (OR 3.05; 95% CI 1.77-5.26), duration of therapy, and number of glucose lowering treatments. Conclusions Prescribing habits for both thiazolidinediones changed immediately following the safety warning. IHD was associated with switching from rosiglitazone; otherwise reasons for change appear to be complex, not directly related to the findings of the meta-analysis


  • Response to Dr Patrick Waller's comment

    by Nicholas Moore, Ron Mann, Gillian Hall, Miriam Sturkenboom

  • Biases affecting the proportional reporting ratio (PRR) in spontaneous reports pharmacovigilance databases: the example of sertindole

    by Nicholas Moore, Gillian Hall, Miriam Sturkenboom, Ron Mann, Rajaa Lagnaoui, Bernard Begaud

    Background: Automated measures of reporting disproportionality in databases of spontaneous reports of adverse drug reactions are an emerging tool to identify drug‐related alerts. Sertindole, a new atypical neuroleptic known to prolong the QT interval, was suspended in November 1998 because the proportion of reports of fatal reactions suggesting arrhythmia among all reports with sertindole was almost ten times higher than that for other atypical neuroleptics in the UK. This excess risk was not predicted in preclinical data and had not been found in premarketing trials.Method: Reporting patterns over time were analysed. Prescription Event Monitoring (PEM) studies and a large retrospective cohort allowed for the comparison of actual death rates with atypical neuroleptics, and to assess which proportion of the deaths that occurred were reported.Results: There were indications of possible skewing of reporting related to notoriety, surveillance and market size effects. Death rates in PEM studies were essentially similar between sertindole and other neuroleptics. Cardiac deaths had been two to three times more often reported than other causes of death.Conclusion: Proportional reporting ratios indicate differential reporting of possible reactions, not necessarily differential occurrence. There was no indication of an actual increase of risk of all causes or cardiac deaths during sertindole treatment, but only an increased risk of its being reported. The suspension of sertindole was rescinded by Committee on Proprietary Medicinal Products (CPMP) in October 2001. Copyright © 2003 John Wiley & Sons, Ltd.